Rescuing a Stalled Cardiovascular Outcomes Trial Through Targeted Operational Intervention When a Phase III cardiovascular outcomes trial (CVOT) faced significant enrollment delays and timeline risk, Julius Clinical was engaged to support and acc...
Executing a Complex Phase III Diabetes Cardiovascular Outcomes Trial in a High-Risk Population Cardiovascular outcomes trials (CVOTs) in type 2 diabetes present a unique combination of clinical, operational, and regulatory complexity, particularl...
Join P95 Julius Clinical at the ENCALS Meeting 2026 in Madrid from 24-26 June. Meet our neuroscience experts at the ENCALS (European Networks to Cure ALS) Meeting to discover how P95 Julius Clinical supports efficient, high-quality clinical devel...
The Netherlands, 09 February 2026Ubiquitous in real-world data (RWD) projects, Electronic Medical Record (EMR) and Electronic Health Record (EHR) data is making its way slowly but surely into clinical trials, and the possibilities appear endle...
Zeist, The Netherlands – 14.05.2025 – Julius Clinical, a leading clinical Contract Research Organization (CRO) with deep therapeutic expertise in CNS and Cardiometabolic indications, today announced continued growth in bookings in these key th...
Zeist, Netherlands, May 14, 2025– Julius Clinical, a leading full-service Contract Research Organization (CRO) headquartered in the Netherlands (Zeist), and Peachtree BioResearch Solutions, a specialized CNS CRO based in the United States (Georg...
A paper published in Clinical Rheumatology from the research group of our Scientific Officer Manuel Castro Cabezas and Chief Scientific Officer Rick Grobbee indicates that patients with rheumatoid arthritis with high liver fibrosis scores are like...
11 February 2025Professor Rick Grobbee, Professor of Clinical Epidemiology at the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht (the Netherlands), and Chief Scientific Officer at Julius Clinical, (Academ...
Julius Clinical is proud to announce our continued sponsorship of Bio-Neuroscience 2025, the premier summit for CEOs, investors, and industry decision-makers in CNS neuroscience drug development.Taking place in Amsterdam from 25-27 February 20...
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThere is a strong association between age, obesity, liver fibrosis and cardiovascular (CV) disease, particularly in the conte...
"*" indicates required fields
"*" indicates required fields
P95 and Julius Clinical have merged to form a leading global, full-service clinical research organization (CRO) with integrated expertise across neuroscience, cardio-renal-metabolic, and infectious diseases and vaccines. Read more here.
